Predicting beta-2 microglobulin rebound after dialysis
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how a protein called beta-2 microglobulin (β2M) changes after your dialysis session. It aims to better understand this protein's levels to help manage your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are able to make your own medical decisions.
- You have end-stage kidney disease and have been on regular hemodialysis for at least 3 months.
- You do not have an active infection (like a cold or flu) within the past 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a protein supplement during dialysis sessions can help people on maintenance dialysis maintain or improve their nutrition. It looks for participants who have been on dialysis for at least three months and are not severely malnourished.
This study measures how well a dialysis method called haemodiafiltration removes waste products from the blood, tracks how patients feel, and monitors sodium balance. It aims to improve treatment for people with kidney failure on dialysis.
This study looks at how well a protein called albumin works in people who are on regular hemodialysis (dialysis for kidney failure). It aims to understand kidney-related health better, and may help improve future care for dialysis patients.
This study looks at how blood flow to the kidneys changes during hemodialysis in people who have just started dialysis. It may help doctors understand how to better protect kidney function.
This trial studies whether a blood test called delta C-cistatin can help doctors predict when patients can safely stop continuous kidney dialysis after acute kidney injury.
This study looks at how different types of dialysis affect salt stored in your tissues and your small blood vessels. It may help doctors understand how to improve dialysis treatments.
Hear when a new Renal Disease, End Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.